Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company, focusing on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate is in Phase 2 clinical trial for the treatment of advanced solid tumors; The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an epidermal growth factor receptor (EGFR) inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.
Zentalis is building a vibrant team of experienced professionals in San Diego that are committed to their common goal: to better the lives of patients impacted by cancer. The company plans to use the laboratory space to advance cancer therapy and treatment research.
The new 120,000- SF research laboratory facility is located in San Diego. The design brings to life a variety of spaces for scientific research with both interior and exterior campus amenities to support a first-class facility. GMC Commissioning provided full commissioning of all systems on this project. A team of four commissioning professionals supported Zentalis’s internal team in delivering this highly complex facility under an extremely tight deadline. Nighttime and weekend work were required to perform all functional testing and meet the published schedule. GMC Cx was proud to turnover this world-class operational, safe, and efficient building to Zentalis.